Evidence syntheses and meta-analyses are used to inform clinical practice guidelines and health economic evaluations. However, heterogeneity of treatment effects poses a significant challenge. Conventional meta-analysis addresses heterogeneity through random-effect assumptions, which are not supported by design and lead to estimates that may not apply to any real-world population. Causally-interpretable meta-analysis (CIMA) offers a rigorous framework for specification, identification, and estimation of causal effects when combining information from multiple randomized trials. Initial development of CIMA focused on using individual data from randomized trials, but such data are often unavailable in practice. Here, we propose a new version of CIMA that only requires aggregate data from trials, addressing the limitations of traditional meta-analysis methods while relying only on aggregate data. The method leverages the trials' reported estimates of marginal and one-at-a-time subgroup treatment effects and descriptive statistics for baseline covariates to build moment equations for identifying and estimating a parametric conditional average treatment effect (CATE) function. The average treatment effect in a new target population is obtained by marginalizing the CATE function over the individual covariate data that defines the target population. The method can also be used to obtain causally-interpretable indirect treatment comparisons in the target population. We establish the asymptotic properties of the method, assess its finite-sample performance in simulation studies, and illustrate the application of the method by re-analyzing a published meta-analysis for SGLT2 inhibitors in patients with heart failure.
原文链接
分享
引用
